Form D · Biotechnology
IMMUNETICS, INC.
Boston, MA · CIK 0001056227
Offering snapshot reported Mar 10, 2014 · SEC filing
- Reported sold
- $835K Offering amount: $3M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Feb 26, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 10, 2014 | Initial | $835,000 | No comparison | 12 | SEC filing |
| Aug 10, 2012 | Initial | $629,090 | No comparison | 24 | SEC filing |
| Apr 10, 2006 | Paper | Not reported | No comparison | Not reported |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-213271
Source: Form D, filed Mar 10, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Stephen Chubb | Director |
| Richard Gibbs | Director |
| Andrew Levin | Director, Executive |
| Richard Pinkowitz | Executive |
| Lois Silverman | Director |
| John Yonkin | Director, Executive |
| Houry Youssoufian | Executive |
| Ron Zwanziger | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
27 Drydock Ave.
Boston, MA, 02210
Boston, MA, 02210